ALDX logo

Aldeyra Therapeutics (ALDX) Cash From Financing

Annual CFF

-$171.40 K
+$1.10 M+86.51%

December 1, 2024


Summary


Performance

ALDX Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherALDXcash flowmetrics:

Quarterly CFF

$7800.00
+$205.20 K+103.95%

December 1, 2024


Summary


Performance

ALDX Quarterly CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherALDXcash flowmetrics:

TTM CFF

-$171.40 K
+$1.02 M+85.61%

December 1, 2024


Summary


Performance

ALDX TTM CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherALDXcash flowmetrics:

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

ALDX Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+86.5%+100.8%+86.5%
3 y3 years-100.1%+100.0%-100.1%
5 y5 years-100.7%-99.9%-100.7%

ALDX Cash From Financing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-100.1%+86.5%-99.3%+100.8%-100.1%+86.9%
5 y5-year-100.1%+86.5%-100.0%+100.8%-100.1%+86.9%
alltimeall time-100.1%+86.5%-100.0%+100.8%-100.1%+86.9%

Aldeyra Therapeutics Cash From Financing History

DateAnnualQuarterlyTTM
Dec 2024
-$171.40 K(-86.5%)
$7800.00(-104.0%)
-$171.40 K(-85.6%)
Sep 2024
-
-$197.40 K(<-9900.0%)
-$1.19 M(-9.0%)
Jun 2024
-
$0.00(-100.0%)
-$1.31 M(+0.4%)
Mar 2024
-
$18.20 K(-101.8%)
-$1.30 M(+2.7%)
Dec 2023
-$1.27 M(-204.1%)
-$1.01 M(+220.6%)
-$1.27 M(+392.5%)
Sep 2023
-
-$315.80 K(-6058.5%)
-$257.90 K(-120.6%)
Jun 2023
-
$5300.00(-89.9%)
$1.25 M(+0.4%)
Mar 2023
-
$52.60 K(>+9900.0%)
$1.25 M(+2.4%)
Dec 2022
$1.22 M(-99.4%)
$0.00(-100.0%)
$1.22 M(0.0%)
Sep 2022
-
$1.20 M(>+9900.0%)
$1.22 M(+1300.8%)
Jun 2022
-
$0.00(-100.0%)
$87.10 K(-99.9%)
Mar 2022
-
$23.30 K(>+9900.0%)
$120.46 M(-38.1%)
Dec 2021
$194.50 M(+364.2%)
$0.00(-100.0%)
$194.50 M(0.0%)
Sep 2021
-
$63.80 K(-99.9%)
$194.50 M(-11.9%)
Jun 2021
-
$120.37 M(+62.5%)
$220.66 M(+95.8%)
Mar 2021
-
$74.06 M(>+9900.0%)
$112.71 M(+169.0%)
Dec 2020
$41.90 M(+77.7%)
$0.00(-100.0%)
$41.90 M(-16.6%)
Sep 2020
-
$26.22 M(+111.1%)
$50.24 M(+29.3%)
Jun 2020
-
$12.42 M(+282.0%)
$38.86 M(+47.1%)
Mar 2020
-
$3.25 M(-61.0%)
$26.42 M(+12.1%)
Dec 2019
$23.58 M(-70.7%)
$8.33 M(-43.9%)
$23.58 M(-71.1%)
Sep 2019
-
$14.84 M(<-9900.0%)
$81.53 M(+20.3%)
Jun 2019
-
-$9100.00(-102.2%)
$67.80 M(-11.8%)
Mar 2019
-
$407.60 K(-99.4%)
$76.84 M(-4.6%)
Dec 2018
$80.53 M
$66.29 M(+5855.9%)
$80.53 M(+463.7%)
DateAnnualQuarterlyTTM
Sep 2018
-
$1.11 M(-87.7%)
$14.29 M(-64.3%)
Jun 2018
-
$9.03 M(+120.6%)
$40.00 M(+29.3%)
Mar 2018
-
$4.09 M(+8427.7%)
$30.94 M(-17.3%)
Dec 2017
$37.43 M(+193.8%)
$48.00 K(-99.8%)
$37.43 M(+0.0%)
Sep 2017
-
$26.83 M(<-9900.0%)
$37.42 M(+256.8%)
Jun 2017
-
-$29.70 K(-100.3%)
$10.49 M(-55.1%)
Mar 2017
-
$10.58 M(>+9900.0%)
$23.33 M(+83.2%)
Dec 2016
$12.74 M(-55.3%)
$36.10 K(-135.4%)
$12.74 M(+0.4%)
Sep 2016
-
-$102.10 K(-100.8%)
$12.69 M(-0.5%)
Jun 2016
-
$12.81 M(<-9900.0%)
$12.75 M(-34.3%)
Mar 2016
-
-$9700.00(-31.7%)
$19.42 M(-31.8%)
Dec 2015
$28.47 M(+183.1%)
-$14.20 K(-60.8%)
$28.47 M(-0.0%)
Sep 2015
-
-$36.20 K(-100.2%)
$28.48 M(+0.5%)
Jun 2015
-
$19.48 M(+115.5%)
$28.34 M(+48.0%)
Mar 2015
-
$9.04 M(>+9900.0%)
$19.15 M(+90.4%)
Dec 2014
$10.05 M(+168.5%)
$0.00(-100.0%)
$10.05 M(-9.9%)
Sep 2014
-
-$176.80 K(-101.7%)
$11.15 M(-15.9%)
Jun 2014
-
$10.28 M(<-9900.0%)
$13.27 M(+351.0%)
Mar 2014
-
-$52.80 K(-104.8%)
$2.94 M(-21.4%)
Dec 2013
$3.75 M(+113.9%)
$1.10 M(-43.3%)
$3.75 M(+41.5%)
Sep 2013
-
$1.94 M(-4746.3%)
$2.65 M(+273.4%)
Jun 2013
-
-$41.70 K(-105.6%)
$708.70 K(-5.6%)
Mar 2013
-
$750.40 K
$750.40 K
Dec 2012
$1.75 M(>+9900.0%)
-
-
Dec 2011
$0.00
-
-

FAQ

  • What is Aldeyra Therapeutics annual cash flow from financing activities?
  • What is the all time high annual CFF for Aldeyra Therapeutics?
  • What is Aldeyra Therapeutics annual CFF year-on-year change?
  • What is Aldeyra Therapeutics quarterly cash flow from financing activities?
  • What is the all time high quarterly CFF for Aldeyra Therapeutics?
  • What is Aldeyra Therapeutics quarterly CFF year-on-year change?
  • What is Aldeyra Therapeutics TTM cash flow from financing activities?
  • What is the all time high TTM CFF for Aldeyra Therapeutics?
  • What is Aldeyra Therapeutics TTM CFF year-on-year change?

What is Aldeyra Therapeutics annual cash flow from financing activities?

The current annual CFF of ALDX is -$171.40 K

What is the all time high annual CFF for Aldeyra Therapeutics?

Aldeyra Therapeutics all-time high annual cash flow from financing activities is $194.50 M

What is Aldeyra Therapeutics annual CFF year-on-year change?

Over the past year, ALDX annual cash flow from financing activities has changed by +$1.10 M (+86.51%)

What is Aldeyra Therapeutics quarterly cash flow from financing activities?

The current quarterly CFF of ALDX is $7800.00

What is the all time high quarterly CFF for Aldeyra Therapeutics?

Aldeyra Therapeutics all-time high quarterly cash flow from financing activities is $120.37 M

What is Aldeyra Therapeutics quarterly CFF year-on-year change?

Over the past year, ALDX quarterly cash flow from financing activities has changed by +$1.02 M (+100.77%)

What is Aldeyra Therapeutics TTM cash flow from financing activities?

The current TTM CFF of ALDX is -$171.40 K

What is the all time high TTM CFF for Aldeyra Therapeutics?

Aldeyra Therapeutics all-time high TTM cash flow from financing activities is $220.66 M

What is Aldeyra Therapeutics TTM CFF year-on-year change?

Over the past year, ALDX TTM cash flow from financing activities has changed by +$1.10 M (+86.51%)